Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Tito Ghosh"'
Autor:
Noa Cleveland, Benjamin Chastek, Tito Ghosh, Ninfa Candela, Timothy Bancroft, Tao Fan, Kandavadivu Umashankar, David Rubin
Publikováno v:
Gastroenterology. 162:S8-S9
INTRODUCTION Inadequate response, loss of response, or intolerance to a first-line biologic typically requires patients with ulcerative colitis (UC) to switch treatment to a second-line biologic therapy. However, the clinical outcomes of patients rec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ea1cd95888adeb048bfdd74a7154f75
https://doi.org/10.1053/j.gastro.2021.12.024
https://doi.org/10.1053/j.gastro.2021.12.024
Autor:
Frank Scott, Anita Afzali, Parambir Dulai, Mei Lu, Ninfa Candela, Tao Fan, Tito Ghosh, James Lewis
Publikováno v:
Inflammatory Bowel Diseases. 28:S11-S12
BACKGROUND There has been an ongoing expansion in available biologic and small molecule therapies to treat moderate to severe ulcerative colitis (UC). The sequence in which these therapies are used has been a topic of high interest among clinicians.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af7781956468110f05017706924cb1a7
https://doi.org/10.1093/ibd/izac015.018
https://doi.org/10.1093/ibd/izac015.018
Autor:
Niranjan Kathe, Kandavadivu Umashankar, Kirti Mirchandani, Arunima Hait, Riyanka Paul, Tito Ghosh, Ninfa Candela, Tao Fan
Publikováno v:
Inflammatory Bowel Diseases. 28:S9-S10
BACKGROUND In the real-world clinical setting, patients with moderate-to-severe ulcerative colitis (UC) may undergo dose escalation when they lose response to their prescribed biologic treatment. Such dose escalation of biologic agents has an impact
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f51dcf96bd598b2a2c3c81ee6461f2ac
https://doi.org/10.1093/ibd/izac015.015
https://doi.org/10.1093/ibd/izac015.015